<DOC>
	<DOCNO>NCT00043953</DOCNO>
	<brief_summary>The objective study explore metabolic toxicity associate lopinavir/ritonavir ( LPV/r ) plus saquinavir mesylate ( INV ) versus LPV/r plus Combivir antiretroviral naïve subject assess overall safety , tolerability efficacy LPV/r plus INV versus LPV/r plus Combivir antiretroviral naïve subject assess pharmacokinetics 400 mg INV take twice day ( BID ) , 600 mg INV BID 800 mg INV BID combination 400 mg lopinavir/100 mg ritonavir plus 150 mg lamivudine/300 mg zidovudine BID .</brief_summary>
	<brief_title>Lopinavir/Ritonavir Combination With Saquinavir Mesylate Lamivudine/Zidovudine Explore Metabolic Toxicities Antiretroviral HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Subject naïve antiretroviral treatment ( subject may 7 day antiretroviral treatment ) . Subject least 18 year age , inclusive . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) , vasectomized partner , total abstinence sexual intercourse If female , result urine pregnancy test perform screening ( urine specimen obtain earlier 28 day prior study drug administration ) negative . Subject breastfeeding . Vital sign , physical examination laboratory result exhibit evidence acute illness . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic , endocrinologic , metabolic hepatic disease would opinion investigator adversely affect his/her participate study . Subject require agrees take follow medication duration study : midazolam , triazolam , terfenadine , astemizole , cisapride , pimozide , propafenone , flecainide , certain ergot derivative ( ergotamine , dihydroergotamine , ergonovine , methylergonovine ) , rifampin , lovastatin , simvastatin , St. John 's wort . Subject agrees take medication study , include overthecounter medicine , alcohol recreational drug without knowledge permission principal investigator . Subject treat active AIDSdefining opportunistic infection within 30 day screen . Subject plasma HIV RNA level great 400 copies/mL screening . Subject agrees take dos study drug bottle provide sponsor ( rather container , i.e. , `` pill box '' ) . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . Subject history allergic reaction significant sensitivity LPV/r , INV Combivir . Subject history substance abuse psychiatric illness could preclude adherence protocol . Screening laboratory analysis show follow abnormal laboratory result : Hemoglobin ≤ 10.0 g/dL Absolute neutrophil count ≤ 1000 cells/µL Platelet count ≤ 50,000 per mL ALT AST ≥ 3.0 x Upper Limit Normal ( ULN ) Creatinine ≥ 1.5 x Upper Limit Normal ( ULN ) Subject receive investigational drug within 30 day prior study drug administration . For reason , subject consider investigator unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>treatment naive</keyword>
</DOC>